Lonza

This October marked a major business milestone for Lonza, as we completed the acquisition of our large-scale manufacturing facility in Vacaville from Roche. Join us to look back on an eventful celebration in Vacaville, as we came together to welcome more than 750 new colleagues into our global Biologics network. #Biologics #Acquistion #Lonza #Vacaville

Lonza is at BIO-Europe next month and excited to meet with you. Schedule some time with us using the partnering portal: https://lnkd.in/dSh2WhAN Or stop by and see us at booth #618. See you there!

A huge Thank You to everyone we connected with at American Association of Pharmaceutical Scientists (AAPS) | @aapscomms PharmSci 360! Engaging with so many of you was fantastic —whether you visited our booth, attended our partner presentation and poster sessions, or joined us at our networking event. Your insights, questions, and conversations made this year’s AAPS an inspiring experience. We look forward to staying in touch to explore future collaboration opportunities. In the meantime, you can visit our website to find out more about our expert small-molecule drug development capabilities: https://lnkd.in/d3AQE6cQ #LonzaSM #WeWorkAsOne #SmallMolecules #AAPS #PharmSci360

Explore the latest advancements in respiratory delivery of biologics! Join us on November 12 at 11 AM EST | 5 PM CET for an in-depth look at how excipients are driving innovation in inhalation therapies. Hear from Kimberly Shepard, PhD and Michael Shultz, PhD, from Lonza Small Molecules and Diana Fernandes, PhD from invoX Belgium (formerly Softhale NV) as they share insights into regulatory landscapes, API stabilization, and the unique formulation requirements of liquid and dry dosage forms. This webinar is perfect for scientists, CMC leads, and biotech innovators focused on respiratory therapies. 📅 Reserve your spot here: https://lnkd.in/dAtSuAGB #RespiratoryBiologics #DrugDevelopment #LonzaSM #WeWorkAsOne #SmallMolecules

Join us at booth #15 for the International mRNA Health Conference in Boston, Massachusetts. While you're there, be sure to catch our presentation: 🎤 𝗧𝗵𝗲 𝗜𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝗰𝗲 𝗼𝗳 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗮 𝗠𝗼𝗱𝘂𝗹𝗮𝗿 𝗺𝗥𝗡𝗔/𝗟𝗡𝗣 𝗧𝗼𝗼𝗹𝗯𝗼𝘅 Wednesday, 13 November 4:55pm Sönke Stocker Executive Director, Innovation and Strategic Growth

The recent webinar given by Lonza experts Josh Marsh and Abhijeet Sinha can now be watched on demand. They have explained how we use tools such as physiologically based pharmacokinetic (PBPK) modeling and solid form screening to address solubility challenges in new chemical entities, helping them progress to the clinic as efficiently as possible. You can now watch the webinar for free here: https://lnkd.in/d4TPUmTf. If you have any bioavailability challenges, feel free to reach out. We would be pleased to discuss how Lonza can assist you.   #SmallMolecules #LonzaSM #WeWorkAsOne #SolidFormScreening #PBPK

What are the differences between biologics and cell and gene therapy manufacturing, and where can knowledge sharing improve some of the challenges associated with cell culture media formulation? Alexis Bossie, Director of Media R&D at Lonza and Sanjay Kumar, Global SME for CGT & Biologics Media at Lonza, recently gave an interview with The Medicine Maker to answer these questions. Read the full interview here: https://lnkd.in/diuBQ7df #AHealthierWorld #Biologics #CellTherapy #GeneTherapy #Biotechnology

This weekend, Lonza celebrates 127 years of innovation and growth. Lonza was founded as a hydroelectricity company to support the production of Carbide at a time when this sustainable source of new energy was in its infancy. Our founder and first ever CEO – Alfons Ehinger – took a calculated leap of faith in this innovative new technology, leaving the city of Basel for Gampel in the canton of Valais. In doing so, he laid the foundations of our company and encoded a strong spirit of entrepreneurialism in our company’s DNA that has kept us on the move ever since. It continues to drive all of us at Lonza onward and upward, both today and in the years to come.   Learn more about where we come from and how we have continued to reinvent ourselves over and over again to create new business models, capture new markets, and serve the changing needs of the world around us for 127 years. Take a look at our Lonza history video below, and at our Lonza Archive Restoration Project here: https://lnkd.in/dgSnWXu4

We’re excited to invite you to join us for an engaging webinar about how we’re improving expression control of biotherapeutic proteins on Tuesday, 19th November at 11 am ET | 5 pm CET. As the industry moves towards the production of diverse, next-generation protein formats, our expert Peter O'Callaghan will take a look into the challenges associated with this and how Lonza is developing enhanced GS® vector technology to enable better control of expression in CHOK1SV GS-KO® cells, enhance titers, and improve stability for a range of biotherapeutic formats. This is a fantastic opportunity to learn from the industry expert and ask questions. Whether you're looking to expand your knowledge or simply curious about the latest developments in Lonza’s expression technologies, we encourage you to register! 📅 Date: Tuesday, 19th November 🕒 Time: 11 am ET | 5 pm CET 🔗 Register here: https://lnkd.in/eqZ8eybg We look forward to seeing you there! #Webinar #LonzaExpressionSystems #Biotech #Lonza #LonzaInYourLab

In our Q3 qualitative update, we reported performance is on track to deliver on our Full-Year Outlook, with a strong Q3 commercial and operational performance across the CDMO business.   Business highlights in Q3 included a long-term commercial supply agreement with Vertex for CASGEVY®, the first approved gene-edited therapy using CRISPR/Cas-9 technology. We also reached an important milestone on 1 October with the successful closing of the acquisition of the large-scale manufacturing site in Vacaville from Roche.   Read more here: https://lnkd.in/dEeneWmy   #AHealthierWorld #AMeaningfulDifference #PharmaceuticalManufacturing